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Abstract Background New drugs and new formulations
enter the growing market for ADHD medication. The
growing awareness of possible persistence of ADHD
impairment beyond childhood and adolescence resulting in
increased pharmacotherapy of ADHD in adults, is also a
good reason for making an inventory of the what is generally
known about pharmacotherapy in ADHD. Aim To discuss
current issues in the possible pharmacotherapy treatment of
ADHD in children, adolescents and adults with respect to the
position of pharmacotherapy in ADHD treatment guidelines,
the pharmacoepidemiological trends, and current concerns
about the drugs used. Methods A search of the literature with
an emphasis on the position of pharmacotherapy in ADHD
treatment guidelines, the pharmacoepidemiological trends,
and current concerns about the drugs used in pharmaco-
therapy. Results According to the guidelines, the treatment
of ADHD in children consists of psychosocial interventions
in combination with pharmacotherapy when needed. Stim-
ulants are the first-choice drugs in the pharmacological
treatment of ADHD in children despite a number of well
known and frequently reported side effects like sleep dis-
orders and loss of appetite. With regard to the treatment of
adults, stimulant treatment was recommended as the first-
choice pharmacotherapy in the single guideline available.
Both in children and adults, there appears to be an additional
though limited role for the nonadrenergic drug atomoxetine.
The increase of ADHD medication use, in children, ado-
lescents and in adults, can not only be interpreted as a sign of
overdiagnosis of ADHD. Despite the frequent use of stim-
ulants, there is still a lack of clarity on the effects of long-
term use on growth and nutritional status of children. Car-
diovascular effects of both stimulants and atomoxetine are
rare but can be severe. The literature suggests that ato-
moxetine may be associated with suicidal ideation in chil-
dren. Conclusion Although pharmacotherapy is increasing
common in the treatment of ADHD in both children and
adults, there are still a lot of questions about side effects and
how best to counter them. This suggests an important role for
close monitoring of children and adults treated with stimu-
lants or atomoxetine.
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Impact of findings on practice
• Stimulants are the first-choice drugs in the pharmaco-
logical treatment of ADHD in children as well as in
adults, despite a number of well known and frequently
reported side effects.
• Physicians need to be aware that also rare and possibly
severe adverse events might come up as prevalence of
use increases.
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• Little is known about specific efficacy and safety issues
in the use of ADHD medication by adolescents and
adults despite the increase of use in these age categories.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is the
most common psychiatric disorder among children and
adolescents [1]. ADHD is, with a prevalence of 3–7% in
school-aged children, considered a major clinical and
public health problem because of the association with
morbidity and disability in youths and adults [2]. Although,
the diagnostic criteria for school-aged children are neutral
with respect to gender and age, ADHD is more prevalent
among boys than girls with ratios varying from 3:1 to 5:1 in
epidemiological studies [3, 4]. Part of this disparity may
result from different identification rates, as the disruptive
component of the disorder may be less prominent in girls in
an educational setting [5]. This type of ADHD where the
inattentive component is predominant and the hyperactivity
component not present is called attention-deficit disorder
(ADD).
ADHD was for long considered a childhood disorder.
Nowadays there is growing public and professional
awareness that ADHD is also a significant source of
impairment for many adults [4, 6, 7]. Although the persis-
tence of ADHD beyond childhood is established, it is dif-
ficult to determine the extent of this persistence. Different
studies suggest that between one-third and two-thirds of
children with ADHD will continue to have disabling
symptoms as adults [6–9]. This broad range in persistence is
likely to be explained by variation in the diagnostic criteria
used, selection criteria, sources of information, changes in
source of information, and changes in diagnostic criteria [4,
10, 11]. Depending on clinical measures used and the way
diagnostic criteria were applied in different studies, the
prevalence of ADHD in adults is estimated 1–4% [12–15].
Diagnostic prevalence of ADHD may be roughly equal for
men and women [6].
The goal of this commentary is to present a general
overview on several current issues around the pharmaco-
therapy of ADHD. In this paper, firstly the possible phar-
macotherapeutical options in the treatment of ADHD, in
children, adolescents, and adults is described. This over-
view is followed by the epidemiology of ADHD medica-
tion use in these different age groups. Then, some concerns
caused by the trend in medication use are discussed taking
into account the developmental perspectives. Finally,
concerns regarding the drugs themselves in different age
groups are summarized. This paper makes no distinction
between ADHD in general and the subtype ADD, unless
specifically needed.
Methods
As there are many developments on various areas concerning
ADHD therapy, we have not tried to do a systematic review.
For illustrative purposes: the number of publications on
pharmacotherapy for ADHD that can be identified by for
example PubMed are around 10,000. Even a meta-review on
articles that have a review label, would yield almost 3,000
hits. So instead of the standard approach we choose for a
commentary of the topics that we, researchers, trained
pharmacists and clinician with a special interest in ADHD,
identified as issues currently under debate in particular, but
by no means limited to, the Netherlands. This resulted in the
themes mentioned (pharmatherapeutical options, pharmaco-
epidemiological trends and concerns about ADHD medica-
tion due to adverse effects), and in particular in the inclusion
of all age groups in this paper. Consequently, per theme,
information is presented for children, adolescents and adults.
After selecting the themes, literature was collected per
item using PubMed. Papers published in languages other
than English, Dutch and German were excluded before
screening. Completeness of literature was not a primary
aim but general coverage was nevertheless controlled for to
some extent by comparing the papers we identified and
used with those identified in published review papers.
Pharmacotherapy of ADHD
Children and adolescents
Pharmacotherapeutical treatment of children with behav-
ioural problems resulting from psychiatric disorders is a
sensitive subject. In guidelines for the treatment of ADHD,
however, pharmacotherapy, psychosocial interventions and
the combination of the two are mentioned as a valid
treatment option [16–21]. Since most ADHD children have
comorbid disorders, combination of different treatment
modalities is usually indicated [16, 17, 19].
In both European and US guidelines, stimulants
(including methylphenidate and dexamphetamine) are
mentioned as the first-choice drugs in the pharmacological
treatment of ADHD [16–21]. Several short-term clinical
trials have demonstrated a significant reduction of ADHD
symptoms in children and adolescents compared to placebo
[22, 23]. In approximately 70% of the children with ADHD,
treatment with stimulants improved symptoms of hyperac-
tivity, impulsivity, and inattention [22]. In addition to
improving core symptoms of ADHD, stimulants also
improved associated behaviour, including on-task behav-
iour, academic performance and social functioning on a
short term. There is no study yet showing long-term effects
on academic performance.
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A landmark research project in the study of ADHD treat-
ment is the Multimodel Treatment Study of Children with
ADHD (MTA). In this study, long-term effects of medication
and behavioural treatment for ADHD children was studied.
During the first 14 months, 579 children aged 7–10 years
were assigned to one of four different treatments: intensive
behavioural therapy, intensive medication management,
combination of the two or routine community care. After the
end of the 14-month trial phase, children in the medication
and combination groups showed significantly greater
improvement in ADHD than those in the behavioural or
routine community care groups [24]. After these 14 months,
the MTA became an observational study in which study
subjects were free to choose their own treatment. Analyses of
the 24-month assessment shows that children originally
assigned to the medication or combination arms of the trial
were still doing better than children from the other two groups
in terms of ADHD symptoms, but the differences became
smaller [25]. After 36 months, the differences between the
original groups were no longer apparent among other due to
the changes in treatment and medication management
intensity since the trial period. Overall, all groups did show
symptoms of improvement over baseline [26].
In the Netherlands, methylphenidate is the most fre-
quently used stimulant and the only officially licensed
stimulant for this indication in children aged 6–17 years.
Dexamphetamine is only available as compounded cap-
sules prepared in the pharmacy. Since 2003, extended
release products of methylphenidate are available on the
Dutch market providing the possibility of once-daily dos-
ing. Transdermal products with stimulants as the active
component are not available in the Netherlands yet, nor are
chewing tablets or oral liquids.
The only nonstimulant drug licensed for the treatment of
ADHD is atomoxetine. Atomoxetine is a noradrenergic
drug, available in the Netherlands since 2005. It is offi-
cially licensed for the treatment of ADHD in children and
adolescents aged 6–17. One or two daily doses are required
to reach optimal benefit. Head-to-head trials that allow for
a final comparison of atomoxetine with methylphenidate
with regard to effectiveness are not done yet. In a recent 6-
week study by Newcom et al. [27], effects of atomoxetine
and osmotically released methylphenidate were compared
with placebo. In this study, methylphenidate was more
effective than atomoxetine. They also showed that about
40% of the children who did not respond on either one of
treatments (methylphenidate or atomoxetine) did respond
to the other, suggesting different responders types.
Adults
In contrast with the substantional number of guidelines for
treatment of ADHD in children, there is to our knowledge
only one published guideline for the treatment of ADHD in
adults: the guideline from the British Association for
Psychopharmacology [28]. Both pharmacological and
psychological interventions are recommended in adults
with ADHD. Analogue to what can be read in the guide-
lines for children, stimulants are recommended as first-line
treatment for adults according to this guideline. Also,
atomoxetine is mentioned as first-line treatment.
Wilens reviewed the literature on the use of pharmaco-
therapy in adult ADHD and identified 15 studies on the
efficacy of stimulants and 27 studies on nonstimulant phar-
macotherapy [29]. Wilens also concluded that stimulants and
noradrenergic drugs (atomoxetine) as well as other antide-
pressants like desipramine had a clinically and statistically
significant beneficial effect on ADHD in adults.
In the Netherlands, neither methylphenidate nor dexam-
phetamine, the two available stimulants, are officially labelled
for the treatment of ADHD in adults. Atomoxetine is the only
labelled drug for the treatment of adults although only if
ADHD treatment has already been initiated before the age of
18 years. This implies that in the Netherlands all pharmaco-
therapeutical treatment of newly diagnosed adults is off-label.
Increase of stimulant use and subsequent concerns
During the 90s, a rapid increase of stimulant use was
noticed in several western countries [30–35]. As these
studies looked at stimulants, this section will be limited to
stimulants as well.
Children and adolescents
In the US, the prevalence of stimulant use increased from
three to seven fold among children under 18 years of age
between 1987 and 1996 [35]. Another US study by Castle
et al., estimated that the prevalence of ADHD medication
among children aged 0–19 increased from 2.8% in 2000 to
4.4% in 2005 [36]. They showed that treatment rates grew
more rapidly for girls than for boys. Also in the Netherlands
the use of stimulants by children strongly increased. A study
in the northern part of the Netherlands among children aged
0–19 years showed that the prevalence of stimulant use
increased from 0.15% in 1995 to 0.74% in 1999 and further
to 1.2% in 2002 [32, 37]. Another study in the Netherlands
showed a comparable increase of the prevalence of stimulant
use: from 0.15% in 1995 to 1.0% in 2001 [38]. Here, treat-
ment rates grew more rapidly for boys than for girls.
Adults
In the earlier mentioned study of Castle et al. the preva-
lence of ADHD medication use was estimated for adults
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(C20 years) in addition to children; they concluded that the
prevalence in adults doubled from 0.4% to 0.8% in
between 2000 and 2005. Treatment rates grew more rapidly
for adults than for children and more rapidly for women
than for men [36].
Following discussion
The increased use of stimulants was probably due to the
increasing number of children, adolescents and adults
being diagnosed with ADHD [4] but also to the prolonged
duration of stimulant use [32]. This overall increase use of
stimulants raised global concerns and led to public and
political debates [39–44]. These discussions focussed on
issues like the validity of ADHD as a psychiatric disorder,
the potential overdiagnosis and overtreatment of ADHD
and the risks of treatment with stimulants [33, 42, 45]. It
was also questioned whether the use of stimulants by
children is addictive and facilitates the abuse of other
substances [46, 47].
Overdiagnosis of ADHD?
When people use the term overdiagnosis, they typically
refer to children who are diagnosed with ADHD but should
not be, i.e. the false positives. It was suggested that ADHD
is the diagnosis du jour [48] and that the diagnosis is
desirable for some parents [49]. Sciutto and Eisenburg
evaluated the evidence for and against overdiagnosis of
ADHD [50]. They concluded that it does not appear that
there is currently sufficient evidence to support the public
perception that ADHD is currently systematically being
overdiagnosed. In the Netherlands, where the public dis-
cussion suggested that ADHD was diagnosed by GPs on a
large scale, a national study suggested that the majority of
the children receiving stimulant treatment had got an
ADHD diagnosis from a child psychiatrist [51].
However, overdiagnosis is only one side of the coin of
poor diagnoses. There will also be children who warrant
the diagnosis but go unidentified or undiagnosed, i.e. the
false negatives. There is scientific evidence that girls have
been and may be consistently under identified and under-
diagnosed [52, 53]; as they suffer more often from the
ADD where the disruptive component is less prominent.
Nonetheless, the reduction of any kind of diagnostic fail-
ures, whether false positive or false negative, is desirable.
Stimulant abuse and stimulant misuse
The increased use of stimulants led, among others, to the
question whether the use of stimulants is addictive and
might facilitate the abuse of other substances.
No cases of addictive effects of methylphenidate, when
used as prescribed, have been reported so far. Children
with ADHD treated with stimulants have been shown to
develop less rather than more substance abuse than
untreated children [46, 47].The results of a meta-analysis
confirmed these findings [54].
Nevertheless, there is sufficient literature to suggest that
stimulants themselves are misused by individuals both with
and without ADHD. In a recent literature review [55] rea-
sons for use, misuse and diversion of stimulants include to
concentrate, improve alertness, ‘get high’, or to experiment.
Concerns about using ADHD drugs––adverse events
As the above shows, major concerns about careless pre-
scribing of stimulants are not warranted. However, this
does not diminish the concerns about the drugs themselves.
Besides the worries about the disease being a psychiatric
disorder while living in a social environment, parents and
physicians might also worry about adverse events of the
drugs and the long-term effects on the development of the
children. Because stimulants have been available for a
considerable period of time and because they are the most
commonly used pharmacotherapy, especially adverse
events of this drug class are mostly discussed in the fol-
lowing paragraphs.
Children and adolescents
Adverse events can be very harsh for patients and their
parents. This burden is even harder when one realizes that
stimulants do not cure the disease but only treat the
symptoms, leading to long-term use of the drugs. Luckily,
most adverse events of stimulants are relatively mild. In a
Dutch survey among parents of stimulant users less than
16 years old, 264 parents (29%) reported their child suf-
fering from inconvenient adverse effects. Most frequently
mentioned by these parents were sleep problems (51%) and
loss of appetite (42%) [51].
Insomnia is a frequently occurring problem in both
treated and untreated children with ADHD which makes
sleep problems such a hard to study adverse effect of
ADHD medication [56]. In the earlier mentioned Dutch
nationwide survey, physicians reported for 22% of children
treated with stimulants, sleep disorders as adverse events.
Since another 18–25% of all physicians indicated not
knowing whether or not the child was suffered from sleep
problems this proportion is probably even higher [51]. It is
unclear to what extent these sleep disorders are related to
ADHD or to the treatment of the disease with stimulants. A
systematic review [57] of not drug treated ADHD children
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showed that children with ADHD have higher apnea–
hyponea indexes compared to non-ADHD children. The
authors found limited evidence from subjective studies
suggesting no significant differences in sleep-onset diffi-
culties and bedtime resistance between children with and
without ADHD.
Sleep disorders whether secondary to ADHD medication
or not, appear increasingly treated with melatonin. In the
Dutch survey of 2003, 11% of the parents of stimulant
using children under 16 years old reported their child used
melatonin [51]. From a cohort of new users (aged 6–17) of
ADHD medication between 2003 and 2006, 14% had
melatonin dispensed within 1 year after starting ADHD
therapy. Use of melatonin was highest among the youngest
children (personal communication, data not yet published).
Little is known regarding the use and efficacy of melatonin
among ADHD children. Van der Heijden et al. found that
melatonin advanced the sleep–wake rhythms and endoge-
nous melatonin. Administering melatonin enhanced total
time asleep and chronic sleep-onset insomnia in medica-
tion-free ADHD children. However, no effect was found on
behaviour, cognitive performance, or quality of life [58].
So, children with ADHD might benefit from melatonin but
the evidence is not plenty.
Stimulants may affect appetite and growth of children
with ADHD; the magnitude of this effect has been contro-
versial for many years. Loss of appetite was reported for
13–60% of ADHD paediatric patients and parents worry
about possible growth reduction resulting from this loss of
appetite [51, 59]. Two major reviews examined all available
data and both concluded that stimulant therapy may be
associated with a reduction in expected height gain, at least
in the first 1–3 years of treatment [60, 61]. However, the
deficits in height and weight do not appear to be a clinical
concern for most children treated with stimulants [60]. The
slight reduction in height and weight seems to be dose
related [62]. If necessary, dose could be lowered [21]. The
effect of drug holidays to reduce growth effects of stimu-
lants is ambiguous [63, 64]. With this lack of clarity about
the magnitude of the impact of stimulant use on growth,
children treated with stimulants need to have their height
and weight measured regularly, for example semi-annually.
The importance of good nutrition should be pointed out to
parents. Therefore, it is worrisome that the results of the
Dutch survey revealed that almost one-fifth (19%) of the
Dutch children on stimulant therapy did not receive follow-
up care concerning treatment with stimulants, implying that
no appointment was scheduled or requested by the medical
doctor according to the parents [51]. This percentage is
worrisome as transfer of prescribing responsibility further
increased the risk of not receiving any follow-up care.
These findings call for efforts to improve collaboration
between primary and secondary care.
Rare but more severe adverse effects of both stimulants
and atomoxetine are possible cardiovascular effects. Both
drug classes can increase blood pressure, heart rate, and
cardiac rhythm, though mostly on a clinically insignificant
level [65, 66]. In 2005, Health Canada briefly suspended
Adderall XR (mixed amphetamine salts) in reaction to 12
cases of sudden death in children and adolescents. How-
ever, a review by the US Food and Drug Administration
(FDA) concluded that sudden death rate for children on
stimulants did not exceed the base rate in the general
population. The FDA concluded that stimulants should be
cautiously used in children and adolescents with pre-
existing heart disease [67]. Furthermore, atomoxetine has
been associated with an increased rate of suicidal ideation
among children [68]. After performing a meta-analysis
recently, Bangs et al. [69] also concluded that although
uncommon, suicidal ideation was significantly more fre-
quent in paediatric ADHD patients treated with atomoxe-
tine compared to those treated with placebo. However,
frequencies of suicide-related events in paediatric patients
with ADHD did not differ between methylphenidate and
atomoxetine treatments. More studies are required to
investigate this rare but very serious adverse event.
Because atomoxetine is a relative new treatment option,
it is even more important for children and adolescents
treated with this drug that they are well-monitored and do
receive regular physical check-ups.
Adults
As far as we know, no large scale study on adverse events
of ADHD medication among adults was published. How-
ever, results from different trials showed a comparable
pattern of adverse events. Headache, decreased appetite
and insomnia were frequently seen among adults using
methylphenidate or amphetamines [70–72].
Conclusion
Overall, pharmacotherapy of ADHD in children is proven
to be effective. Especially for stimulants, and methylphe-
nidate in particular, there is an abundance of evidence. In
contrast to many other drugs used by relatively large pro-
portions of children, drugs for treating ADHD are licensed
and on-label for children. Although ADHD medication is
increasingly used by adolescents and adults, not much is
published on specific efficacy and safety issues in these age
categories. In general, we may conclude that stimulant use
increased over the years, and that there is a lack of studies
on long-term effects of ADHD drugs in all ages.
Since the use of atomoxetine is new and on a relatively
small scale, not much is known yet about adverse events of
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this drug. This may bias the atomoxetine-stimulants dis-
cussion in favour of the first.
Although stimulants have been used for decades, as
prevalence of use increases, physicians need to be aware
that also rare and possibly severe adverse events might
come up. Also, the increased longevity of ADHD medi-
cation use may give rise to new concerns and stresses the
importance of monitoring people who use this medication
for such a long period.
Last decade there is an increasing awareness that ADHD
persists into adulthood for many patients. More research on
the symptoms, starting treatment, and adverse events
among adult ADHD patients is needed to get more insight
in the pros and cons of ADHD medication use in this
specific population.
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